Jan 30 (Reuters) - Regeneron Pharmaceuticals will acquire development and commercialization rights of experimental immune cell therapies from 2seventy bio and form a new research and development unit for these therapies, the companies said on Tuesday. (Reporting by Leroy Leo in Bengaluru; Editing by Savio D'Souza)
Donald Trump’s aides have drawn up secret plans to oust the chairman of the Federal Reserve and allow the president to set interest rates, according to reports.
Walmart's CEO went from earning $6.50 an hour to $25 million a year—here are his three tips for climbing the corporate ladder like him
These proven wealth builders could be exactly what you're searching for right now.
There's a much more popular AI stock on Capitol Hill than the leading AI chip maker.
Here's what could happen next to Microsoft shares.
The property report includes 85 major metropolitan areas in the U.S. with populations of at least 750,000.
It's been an "everything buy bonds" bull rally in markets for months, but BofA is cautiously watching a couple of indicators.
Nvidia and Super Micro Computer have been the best-performing S&P 500 stocks of 2024, but select Wall Street analysts still see substantial upside for shareholders.
Put your money to work by investing in these three high-quality dividend stocks.
Jamie Dimon and Jerome Powell are taking the European viewpoint on soaring debt levels in the U.S.